ALEGRO Completes Agreement to Provide Ablatherm'C' Prostate Treatment in Canada.TORONTO -- Alegro Health Corp. ("Alegro") (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:AGO) is pleased to announce that the Company has successfully completed negotiations for the Company's Don Mills Surgical Unit Inc. ("DMSU DMSU Digital Main Switching Unit DMSU Divisional Mobile Support Unit DMSU Disaster Medical Support Unit ") to provide the facilities and staff for the innovative Ablatherm(C) prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. treatment. DMSU is currently the only facility in North America where the treatment is being offered to patients. The Agreement is with Maple Leaf HIFU HIFU High-intensity focused ultrasound Surgery A method that focuses ultrasound to heat/ablate target tissue without injuring surrounding structures. See Sonablate 200™. Company, which holds the exclusive Canadian rights to the Ablatherm(C) process. The Ablatherm(C) Treatment, a breakthrough, non-invasive procedure, was developed by EDAP EDAP Eating Disorders Awareness and Prevention EDAP Extended Data Availability and Protection (fault tolerant disk technology) EDAP Emergency Department Approved for Pediatrics EDAP Energy Descent Action Plan TMS TMS Transcranial Magnetic Stimulation (alternative medicine for depression) TMS Test Match Special (sports - cricket) TMS Texas Motor Speedway TMS Transportation Management System TMS Toyota Motor Sales S.A. of France and has been in use in Europe with great success since 1993. To date, in excess of 6,500 Ablatherm(C) procedures have been performed, with exceptional results. Despite increased public awareness of prostate cancer prevention and early detection, new cases continue to increase in number. It is estimated that the United States, where the treatment is unavailable, has approximately 250,000 new cases reported annually. "We are very excited about the opportunity to provide Ablatherm(C) treatment at our DMSU facility" said Dr. William L. Orovan, Superintendent of DMSU. "The Ablatherm(C) treatment is simple, proven and non-invasive. It's great for the patients, great for the company". In addition to being the Chair of the Department of Surgery at McMaster University, and an Alegro Health Corp. director, Dr. Orovan is a practicing Urologist and surgeon. About ALEGRO HEALTH CORP. Alegro Health Corp. is a Canadian healthcare service provider. The Company is listed on the TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. under the symbol "AGO". (www.alegrohealth.com). The TSX Venture Exchange does not accept responsibility for the adequacy of this news release. ALEGRO cannot guarantee that any forward looking statements contained in this news release will materialize. Nor is it possible for ALEGRO to commit itself to updating information about risks and other factors pertaining to its business that might appear in this or any other disclosure documents. Alegro Health Corp. (TSX VENTURE:AGO) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion